Here are a few analogies for Larimar Therapeutics:

• A potential "Vertex Pharmaceuticals for Friedreich's ataxia."
• An early-stage biotech akin to a young Alnylam Pharmaceuticals, pioneering treatments for rare genetic diseases.

• CTI-1601: A lead product candidate in Phase 1 clinical trial for the treatment of Friedreich's ataxia.

Larimar Therapeutics (LRMR) is a clinical-stage biotechnology company. As described, its lead product candidate, CTI-1601, is currently in Phase 1 clinical trials for the treatment of Friedreich's ataxia.

Because Larimar Therapeutics is still in the research and development phase and has not yet brought any products to market, it does not currently have commercial customers in the traditional sense (i.e., companies or individuals purchasing its products).

Its "customers" in the future, upon successful development and approval of its drug candidates, would primarily be individuals (patients) suffering from the rare diseases it targets, such as Friedreich's ataxia. These drugs would likely be prescribed by healthcare professionals and distributed through pharmacies or healthcare systems, but the ultimate beneficiaries and users would be patients.

Carole Ben-Maimon, MD President and Chief Executive Officer

Dr. Ben-Maimon joined Larimar Therapeutics in December 2016 as President and CEO, bringing over 25 years of pharmaceutical industry experience. She previously worked with Deerfield Management Company, evaluating investment opportunities in the pharmaceutical industry. Dr. Ben-Maimon served as President of Global Pharmaceuticals, a subsidiary of Impax Laboratories, and was President and Chief Operating Officer of Barr Pharmaceuticals' branded female healthcare development business, where she also served as a board member. She founded Alita Pharmaceuticals, serving as its President and CEO. At Teva Pharmaceutical Industries, she was responsible for R&D and public policy in North America. She also played a crucial role in forming the Generic Pharmaceutical Association (now Association for Accessible Medicines) through mergers, serving as its elected board chair for three years.

Michael Celano Chief Financial Officer

Mr. Celano joined Larimar Therapeutics in June 2020, bringing over 40 years of experience as a life science business leader. He has spent more than two decades as a Chief Operating Officer (COO), CFO, and board member for high-growth life science companies. Previously, Mr. Celano was CFO for BioRexis, which was acquired by Pfizer. He also served as CFO of Kensey Nash until its acquisition by DSM. Mr. Celano was the COO and previously CFO of Recro Pharma. He served on the Board of Performance Health, a private equity-funded consumer healthcare products company that was sold to Patterson Medical in a dual-track IPO/business sale process. Earlier in his career, he spent 24 years in public accounting, co-chairing Andersen's U.S. Life Sciences Practice and holding leadership positions with KPMG.

Gopi Shankar, PhD, MBA Chief Development Officer

Dr. Shankar holds the position of Chief Development Officer at Larimar Therapeutics. He is a Fellow and President-elect of the American Association of Pharmaceutical Scientists (AAPS). Prior to joining Larimar, he was Senior Director and Head of Bioanalytical Sciences and Immunogenicity at Janssen Research & Development. Earlier in his career, Dr. Shankar served as Director of Immune Response Assessment and Research at Centocor R&D, a wholly-owned subsidiary of Johnson & Johnson, where he contributed to multiple regulatory approvals and led the publication of white papers that informed U.S. Food and Drug Administration and European Medicines Agency guidance on clinical immunogenicity assessment.

Russell G. Clayton, DO Chief Medical Officer

Dr. Clayton serves as the Chief Medical Officer for Larimar Therapeutics. He previously led clinical development and medical affairs at Alcresta Therapeutics, where he oversaw the design and execution of pivotal clinical studies and developed a medical affairs capability for a new product launch. Before Alcresta Therapeutics, Dr. Clayton was the Senior Vice President of Research and Development at Discovery Labs, a pharmaceutical and medical device company, where he guided the scientific and regulatory efforts that led to the marketing authorization of Discovery's first product.

John Berman Vice President of Finance and Administration

Mr. Berman joined Larimar Therapeutics in January 2017 as Vice President of Finance and Administration (or Operations). He brings over 20 years of experience, including 14 years at Teva Pharmaceutical Industries, where he held various positions of increasing responsibility, most recently as Senior Director of Corporate Alliance Management. Mr. Berman is a Certified Public Accountant and holds the Chartered Financial Analyst designation.

The key risks to Larimar Therapeutics (LRMR), a clinical-stage biotechnology company, are predominantly centered around the challenges inherent in drug development, its financial stability, and its reliance on a single lead product candidate.

1. Clinical Trial Risk (Safety and Efficacy)
   The most significant risk for Larimar Therapeutics stems from the inherent uncertainties of clinical trials, encompassing both the safety and efficacy of its lead product candidate, CTI-1601 (nomlabofusp). The drug has a history of safety concerns, including mortalities observed in non-human primate toxicology studies, which led to a clinical hold by the FDA in the past. More recently, severe allergic reactions (anaphylaxis) were reported in 7 out of 39 participants in an open-label study. While Larimar has implemented mitigation strategies, such as a test dose regimen and pre-medication, and the FDA has acknowledged these measures, the agency will still rigorously evaluate the overall benefit-risk profile. There is also a "binary risk" that if Phase 3 clinical results do not demonstrate statistical significance, the company's stock could significantly decline. Furthermore, although CTI-1601 has received Breakthrough Therapy Designation, this does not guarantee regulatory approval, and the FDA may disagree with the company's trial design or interpretation of data, including the use of frataxin levels as a novel surrogate endpoint for accelerated approval.
2. Financial Risk (Cash Burn and Funding)
   As a clinical-stage company with no commercialized products, Larimar Therapeutics faces substantial financial risk due to its significant "cash burn" and ongoing losses. In September 2025, the company reported approximately US$175 million in cash, with an estimated cash runway of about 22 months. This indicates that Larimar will need to raise additional capital to fund its operations and continued clinical development by late 2026. Any future equity financing efforts could lead to significant dilution for existing shareholders. A challenging capital market environment could force the company into unfavorable financing terms, such as predatory licensing deals or even a fire sale of assets.
3. Dependence on a Single Product Candidate
   Larimar Therapeutics' business is heavily reliant on the successful development and commercialization of a single lead product candidate, CTI-1601, for Friedreich's ataxia. The failure of CTI-1601 in clinical trials or to gain regulatory approval would have a devastating impact on the company's prospects, as its entire value proposition is currently tied to this drug. Additionally, the emergence of competing therapies for Friedreich's ataxia could diminish CTI-1601's market potential, even if it eventually receives approval.

For Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company, the expected drivers of future revenue growth over the next 2-3 years are primarily tied to the advancement and potential commercialization of its lead product candidate, CTI-1601 (nomlabofusp), for Friedreich's ataxia. Given the company's stage of development, significant product sales revenue is not anticipated in the immediate future, with analysts forecasting no revenue next year and continued unprofitability over the next three years. However, key milestones related to CTI-1601 are expected to lay the groundwork for future revenue.

The key drivers for future revenue growth for Larimar Therapeutics include:

1. Regulatory Approval of CTI-1601 (nomlabofusp): Larimar Therapeutics is targeting the submission of a Biologics License Application (BLA) seeking accelerated approval for CTI-1601 in the second quarter of 2026. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to nomlabofusp, which can facilitate an accelerated approval pathway. A successful approval would be a pivotal event, allowing the company to commercialize the product.
2. Commercial Launch of CTI-1601 (nomlabofusp): Following a potential accelerated approval, Larimar is targeting the commercial launch of CTI-1601 in the first half of 2027. This would mark the company's first commercial drug, entering a market with limited treatment options for Friedreich's ataxia, and would be the primary source of product-based revenue.
3. Positive Clinical Trial Data and Advancement of CTI-1601: Continued positive data from ongoing and planned clinical trials are crucial for regulatory success and market adoption. The company anticipates providing an update on data from its ongoing Open Label Extension (OLE) study in the second quarter of 2026. Additionally, Larimar is on track to initiate a global Phase 3 study for CTI-1601 by mid-2025. Successful outcomes from these studies are fundamental for securing approval and building a strong commercial foundation.
4. Strategic Partnerships and Licensing Agreements for CTI-1601: As CTI-1601 progresses through late-stage development and approaches regulatory approval, especially with its Breakthrough Therapy Designation, the company's attractiveness for strategic collaborations or licensing agreements increases. Such partnerships, particularly for commercialization in ex-U.S. markets, could involve upfront payments, research funding, and milestone payments, contributing to the company's revenue streams.

Share Issuance

• In February 2026, Larimar Therapeutics completed an upsized public equity offering of 23 million shares, generating approximately $107.6 million in net proceeds. This offering was initially proposed for $75 million.
• In July 2025, the company conducted a public offering that secured $65.1 million in net proceeds, bolstering its balance sheet and extending its cash runway.

Capital Expenditures

• Larimar Therapeutics reported capital expenditures of -$270,000 in the last 12 months as of a recent filing.
• The net proceeds from recent public offerings are intended to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development and commercialization expenses, which may include capital expenditures.